Toggle navigation
TWunroll
TWunroll
faq
Contact US
#ASH20
Ahmar U. Zaidi, MD (Dr. Z)
drzsicklecell
CTX001 a thread 1/ #ASH20 .@DrAlexisThompsn Intro:- BCL11A is a key regulator of the fetal to adult hemoglobin switch- CRISPR Nobel prize in chemistry to @doudna_lab - can gene editing
Read more
Matthew J. Maurer
MaurerStats
Some #ASH20 DLBCL thoughts and observations. I feel like we are at the tip of a changing landscape for therapy and trial design in DLBCL, both newly dx and R/R.
Read more
Bill Archibald, MD, CFII
DrArchibald1
Cost at #ASH20 5 part series. part 1: #financialtoxicity #financialtoxicity delays care and leads to
Read more
Ajay Major, MD, MBA
majorajay
Tons of great teaching pearls from this phenomenal PET/CT in #lymphoma session. Will start a #thread here. #ASH20 #lymsm First, staging PET for DLBCL is more sensitive than BMBx for
Read more
Graham Collins
graham74GC
#CollinsConclusions -DLBCL1Drugs v cells:• bispecifics come of age- CRR~ 50% DLBCL- step up dosing & subcut CRS- 1L elderly safe & active- v little neurotox• CART- 1L high risk
Read more
Matthew J. Maurer
MaurerStats
Looking forward to moderating oral presentations on biomarkers and prognostication in aggressive #lymphoma with @SoniSmithMD on Monday morning. We have some exciting #ASH20 abstracts to discuss. https://ash.confex.com/ash/2020/webprogram/Se
Read more
Ajay Major, MD, MBA
majorajay
A few highlights from the #ASH20 Blood Drop session on outpatient sickle cell disease management in adults. #threadASH guidelines recommend cognitive impairment screening with simplified questions, as well as at
Read more
Catherine Smith, MD
SmithLabSF
Lots of FLT3i action in the first #AML session of the day! Some takeaways. THREAD #ASH20 #leusm 1)Git + chemo: Of pts achieving FLT3 mutational clearance, only ~30% achieve this
Read more
Timothy Schmidt, MD
TMSchmidtMD
Interesting paper in @BloodAdvances confirms prognostic importance of MRD- in NDMM and RRMM (again!) http://tinyurl.com/yyoygprq . Important context: 5y OS of MRD- in TE NDMM pts was 71%, worse than @WinshipAtEmory
Read more
Amer Zeidan, MBBS, MHS
Dr_AmerZeidan
1) Gearing up for a series of #ASH20 highlights in #AMLsm and #MDSsm and will post threads about main highlights on major topics starting with TP53-mutated AML. This subset of
Read more
Catherine Smith, MD
SmithLabSF
Be still my heart, you know I love me some drug resistance talks! Session 604 was! Some highlights. THREAD. #ASH20 #ASHFromHome #ASHtogether #leusm #ImaHemeDork. 1)First up, on target resistance wins
Read more
=NorthTX Yelak=
NorthTxMSG
The outside-in takeaway of #ASH20. Use your best available treatment early. According to Dr. @jmikhaelmd , the 1, 2 punch outcomes of initial and 1st relapse treatment are prognostic of
Read more
Catherine Smith, MD
SmithLabSF
Ok, one last thread with #FinalFLT3 thoughts on today’s #AML talks. #ASH20 #ASHFromHome #ASHtogether #leusm 1) First, Dr. Andrew Wei with an excellent presentation on AML M16 (sor vs placebo
Read more
Vincent Rajkumar
VincentRK
One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do it? The update of the
Read more
Aaron Logan, MD, PhD — DONATE BLOOD!
hemedoc
I have clinic today so won’t be able to tweet more #ASH20 until later (but that I CAN view all sessions later is amazing). As the meeting draws to a
Read more
Ben Derman
bdermanmd
Lots of great data and abstracts for myeloma this year at #ASH20; here, in no particular order, are my ‘top 10’ myeloma-related abstracts with a focus on clinical relevance #mmsm
Read more
‹
1
2
›
By continuing to use the site, you are consenting to the use of cookies as explained in our
Cookie Policy
to improve your experience.
I agree